Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PEARL E GRIMES

Allopathic & Osteopathic Physicians Dermatology

NPI
1790702751
CMS profile
353327
Location
LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$86,123.26

53 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Incyte Corporation $66,246.10 43
Eli Lilly and Company $8,941.46 5
ABBVIE INC. $4,004.27 3
Avita Medical Americas, LLC $3,556.43 1
Janssen Scientific Affairs, LLC $3,375.00 1

Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PEARL E GRIMES

NPI 1790702751 · CMS profile ID 353327

Allopathic & Osteopathic Physicians / Dermatology

LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1790702751?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PEARL E GRIMES, NPI 1790702751, CMS profile ID 353327. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1790702751?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). PEARL E GRIMES, NPI 1790702751, CMS profile ID 353327. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1790702751?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
PEARL E GRIMES, NPI 1790702751, CMS profile ID 353327, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1790702751?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

53 matching records · $86,123.26 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 53 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–53 of 53.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $36.7201/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997391649 CMS
ABBVIE INC. $36.7201/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997391651 CMS
Incyte Corporation $40.0001/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044355617 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $9,231.44 11
PY2020 $7,966.08 5
PY2021 $11,375.35 7
PY2022 $71,285.79 44
PY2023 $86,123.26 53
PY2024 $22,207.77 25
PY2025 $48,150.55 29

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $140,492.95 36
PY2024 Principal investigator $382,005.24 44
PY2023 Recipient $136,810.50 1
PY2023 Principal investigator $152,270.77 17
PY2022 Principal investigator $162,148.43 58
PY2021 Principal investigator $101,688.35 43
PY2020 Principal investigator $192,146.48 48
PY2019 Principal investigator $166,332.89 77

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

36 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $3,537.36 12/31/2025 Non-covered Recipient Entity
PEARL E GRIMES MD
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects with Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy No dispute reported 06/30/2026 1202534707
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $281.10 12/31/2025 Non-covered Recipient Entity
VITILIGO & PIGMENTATION INSTITUTE
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Zasocitinib in Participants with Nonsegmental Vitiligo. No dispute reported 06/30/2026 1223290096
Principal investigator 1 Incyte Corporation $907.80 11/26/2025 Non-covered Recipient Entity
VITILIGO & PIGMENTATION INSTITUTE OF SOUTHERN CALIFORNIA
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240615796
Principal investigator 1 Incyte Corporation $1,759.00 11/26/2025 Non-covered Recipient Entity
VITILIGO & PIGMENTATION INSTITUTE OF SOUTHERN CALIFORNIA
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240615800
Principal investigator 1 Incyte Corporation $1,182.60 11/26/2025 Non-covered Recipient Entity
VITILIGO & PIGMENTATION INSTITUTE OF SOUTHERN CALIFORNIA
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240615807
Principal investigator 1 Incyte Corporation $800.00 11/13/2025 Non-covered Recipient Entity
VITILIGO & PIGMENTATION INSTITUTE OF SOUTHERN CALIFORNIA
An Open-Label, Phase 2, Safety, and Efficacy Study of Ruxolitinib Cream in Participants With Genital Vitiligo No dispute reported 06/30/2026 1240615811
Principal investigator 1 Incyte Corporation $1,835.10 11/06/2025 Non-covered Recipient Entity
VITILIGO & PIGMENTATION INSTITUTE OF SOUTHERN CALIFORNIA
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240615804
Principal investigator 1 Incyte Corporation $2,430.40 11/06/2025 Non-covered Recipient Entity
VITILIGO & PIGMENTATION INSTITUTE OF SOUTHERN CALIFORNIA
An Open-Label, Phase 2, Safety, and Efficacy Study of Ruxolitinib Cream in Participants With Genital Vitiligo No dispute reported 06/30/2026 1240615817
Principal investigator 1 ABBVIE INC. $1,630.90 11/04/2025 Non-covered Recipient Entity
PEARL E GRIMES
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202520093
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $159.29 11/01/2025 Non-covered Recipient Entity
THE VITILIGO & PIGMENTATION INSTITUTE
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Zasocitinib in Participants with Nonsegmental Vitiligo. No dispute reported 06/30/2026 1223287827
Principal investigator 1 Incyte Corporation $981.90 10/09/2025 Non-covered Recipient Entity
VITILIGO & PIGMENTATION INSTITUTE OF SOUTHERN CALIFORNIA
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240615792
Principal investigator 1 ABBVIE INC. $3,226.70 09/03/2025 Non-covered Recipient Entity
PEARL E GRIMES
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202508330
Principal investigator 1 Incyte Corporation $292.50 08/26/2025 Non-covered Recipient Entity
VITILIGO & PIGMENTATION INSTITUTE OF SOUTHERN CALIFORNIA
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240615788
Principal investigator 1 Incyte Corporation $75,000.00 08/19/2025 Non-covered Recipient Entity
VITILIGO & PIGMENTATION INSTITUTE
Vitiligo: A Retrospective Detailed Assessment of the Clinical and Laboratory Spectrum of Disease No dispute reported 06/30/2026 1240615738
Principal investigator 1 Incyte Corporation $75.00 07/31/2025 Non-covered Recipient Entity
VITILIGO & PIGMENTATION INSTITUTE OF SOUTHERN CALIFORNIA
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240615759
Principal investigator 1 Incyte Corporation $189.00 07/22/2025 Non-covered Recipient Entity
VITILIGO & PIGMENTATION INSTITUTE OF SOUTHERN CALIFORNIA
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240615751
Principal investigator 1 Incyte Corporation $298.00 07/22/2025 Non-covered Recipient Entity
VITILIGO & PIGMENTATION INSTITUTE OF SOUTHERN CALIFORNIA
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240615755
Principal investigator 1 Incyte Corporation $8,000.00 07/22/2025 Non-covered Recipient Entity
VITILIGO & PIGMENTATION INSTITUTE OF SOUTHERN CALIFORNIA
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240615763
Principal investigator 1 Incyte Corporation $344.00 07/22/2025 Non-covered Recipient Entity
VITILIGO & PIGMENTATION INSTITUTE OF SOUTHERN CALIFORNIA
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240615770
Principal investigator 1 Incyte Corporation $94.00 07/22/2025 Non-covered Recipient Entity
VITILIGO & PIGMENTATION INSTITUTE OF SOUTHERN CALIFORNIA
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240615777
Principal investigator 1 Incyte Corporation $1,800.00 07/22/2025 Non-covered Recipient Entity
VITILIGO & PIGMENTATION INSTITUTE OF SOUTHERN CALIFORNIA
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240615780
Principal investigator 1 Incyte Corporation $1,000.00 07/22/2025 Non-covered Recipient Entity
VITILIGO & PIGMENTATION INSTITUTE OF SOUTHERN CALIFORNIA
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240615784
Principal investigator 1 Incyte Corporation $1,057.50 07/10/2025 Non-covered Recipient Entity
VITILIGO & PIGMENTATION INSTITUTE OF SOUTHERN CALIFORNIA
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240615774
Principal investigator 1 Incyte Corporation $292.50 06/19/2025 Non-covered Recipient Entity
VITILIGO & PIGMENTATION INSTITUTE OF SOUTHERN CALIFORNIA
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240615747
Principal investigator 1 ABBVIE INC. $1,440.55 06/03/2025 Non-covered Recipient Entity
PEARL E GRIMES
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202489843
Principal investigator 1 Incyte Corporation $1,835.10 05/27/2025 Non-covered Recipient Entity
VITILIGO & PIGMENTATION INSTITUTE OF SOUTHERN CALIFORNIA
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240615744
Principal investigator 1 ABBVIE INC. $1,556.55 05/07/2025 Non-covered Recipient Entity
PEARL E GRIMES
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202483355
Principal investigator 1 ABBVIE INC. $10,099.00 04/17/2025 Non-covered Recipient Entity
PEARL E GRIMES
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202477580
Principal investigator 1 ABBVIE INC. $5,802.00 04/17/2025 Non-covered Recipient Entity
PEARL E GRIMES
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202477583
Principal investigator 1 ABBVIE INC. $4,583.80 04/17/2025 Non-covered Recipient Entity
PEARL E GRIMES
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202477588
Principal investigator 1 Incyte Corporation $693.00 04/17/2025 Non-covered Recipient Entity
VITILIGO & PIGMENTATION INSTITUTE OF SOUTHERN CALIFORNIA
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240615741
Principal investigator 1 ABBVIE INC. $1,860.40 04/03/2025 Non-covered Recipient Entity
PEARL E GRIMES
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202472312
Principal investigator 1 ABBVIE INC. $1,255.60 03/07/2025 Non-covered Recipient Entity
PEARL E GRIMES
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202461255
Principal investigator 1 Incyte Corporation $1,057.50 01/29/2025 Non-covered Recipient Entity
VITILIGO & PIGMENTATION INSTITUTE OF SOUTHERN CALIFORNIA
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240615826
Principal investigator 1 Incyte Corporation $1,274.40 01/03/2025 Non-covered Recipient Entity
VITILIGO & PIGMENTATION INSTITUTE OF SOUTHERN CALIFORNIA
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240615822
Principal investigator 1 ABBVIE INC. $1,860.40 01/02/2025 Non-covered Recipient Entity
PEARL E GRIMES
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202434075